Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept.
about
Consensus treatment plans for new-onset systemic juvenile idiopathic arthritisDAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.Systemic arthritis in children: a review of clinical presentation and treatmentBiological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.
P2860
Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Use of infliximab in patients ...... itis refractory to etanercept.
@en
type
label
Use of infliximab in patients ...... itis refractory to etanercept.
@en
prefLabel
Use of infliximab in patients ...... itis refractory to etanercept.
@en
P1476
Use of infliximab in patients ...... ritis refractory to etanercept
@en
P2093
M M Katsicas
P304
P577
2005-07-01T00:00:00Z